Systematic review of atorvastatin for the treatment of Alzheimer's disease

作     者：Yuan Sun Genfa Wang Zhihong Pan Shuyan Chen 

作者机构：Department of Gerontology Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200092 China 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2012年第7卷第17期

页      面：1344-1351页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 12[管理学] 1201[管理学-管理科学与工程(可授管理学、工学学位)] 10[医学] 

主　　题：Alzheimer's disease dementia atorvastin diphosphonate systematic review neural regeneration 

摘      要：OBJECTIVE： To assess the clinical efficacy and safety of atorvastatin in the treatment of Alzheimer＇s disease. DATA SOURCES： Medline （1948/2011-04）, Embase （1966/2011-04）, Cochrane Library （Issue 3, 2011）, Chinese National Knowledge Infrastructure （1989/2011-04）, and the Chinese Biomedical Literature Database （1979/2011-04） were searched for randomized clinical trials regardless of language. Abstracts of conference papers were manually searched. Furthermore, Current Controlled Trials （http：//***）, Clinical *** （http：//***）, and Chinese Clinical Trial Registry （http：//***） were also searched. Key words included AIzheimer disease, dementia, cognition, affection, memory dysfunction, hydroxymethylglutaryI-CoA reductase inhibitors, atorvastatin and statins. DATA SELECTION： Randomized controlled trials of grade A or B according to quality evaluation criteria of the Cochrane Collaboration were selected, in which atorvastatin and placebo were used to evaluate the effects of atorvastatin in the treatment of Alzheimer＇s disease. Study methodological quality was evaluated based on criteria described in Cochrane Reviewer＇s Handbook 5.0.1. Revman 5.1 software was used for data analysis. MAIN OUTCOME MEASURES： Clinical efficacy, safety, withdrawal from the studies, and withdrawal due to adverse effects. RESULTS： Two randomized controlled trials were included, one was scale A, and the other was scale B. All patients （n = 710, age range 50-90 years） were diagnosed as probable or possible mild to moderate Alzheimer＇s disease according to standard criteria and treated with atorvastatin 80 mg/d or placebo. There was no difference between the two groups in the final follow-up for Clinical Global Impression of Change scale （WMD = 0.13, 95%CI： 0.15 to 0.40）, the Alzheimer＇s Disease Assessment Scale-cognitive subscale （WMD = 1.05, 95%C1：-3.06 to 6.05）, Mini-Mental State Examination Scale （WMD = 0.77, 95%CI： 0.57 to 2.10）, and the Neuropsy